Vortex Biosciences, Inc.

Vortex Biosciences develops advanced solutions for the capture and analysis of Circulating Tumor Cells (CTCs), facilitating non-invasive cancer diagnostics with innovative technology. Founded in 2010 and headquartered in Pleasanton, US, Vortex Biosciences specializes in liquid biopsy systems. The company is led by CEO Paul Jones and was founded by Elodie Sollier. Its operations focus on the development of unique technologies that enhance cancer research.

Vortex Biosciences raised funding in April 2019 from EMV Capital, reflecting its commitment to advancing oncology diagnostics. Vortex Biosciences specializes in innovative solutions for the capture and analysis of Circulating Tumor Cells (CTCs) derived from tumors. Their flagship product, the VTX-1 Liquid Biopsy System, automates the isolation of viable CTCs from whole blood samples using microfluidic technology, enhancing capture efficiency. The system includes the Vortex Cartridge, which facilitates seamless blood sample processing.

The company primarily serves institutions and biopharmaceutical companies in oncology research across North America, Europe, and Asia. Vortex Biosciences generates revenue through direct sales of its VTX-1 Liquid Biopsy System and associated consumables, including the Vortex Cartridge. The revenue model is based on one-time equipment purchases and ongoing sales of necessary consumables, aligning with industry standards in diagnostics and biopharmaceuticals, while fostering strategic partnerships for enhanced technology integration. Vortex Biosciences aims to expand its product line and enhance market penetration.

Following its recent funding round in April 2019, the company plans to develop new products that improve cancer diagnostics and targeting new markets in Europe and Asia by 2025. The latest funding will support these initiatives, enabling Vortex to broaden its technology adoption within the oncology sector.